1. Home
  2. UHT vs DSGN Comparison

UHT vs DSGN Comparison

Compare UHT & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

UHT

Universal Health Realty Income Trust

HOLD

Current Price

$40.05

Market Cap

552.2M

Sector

Real Estate

ML Signal

HOLD

Logo Design Therapeutics Inc.

DSGN

Design Therapeutics Inc.

BUY

Current Price

$10.52

Market Cap

579.9M

Sector

Health Care

ML Signal

BUY

Company Overview

Basic Information
Metric
UHT
DSGN
Founded
1986
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
552.2M
579.9M
IPO Year
1995
2021

Fundamental Metrics

Financial Performance
Metric
UHT
DSGN
Price
$40.05
$10.52
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$15.25
AVG Volume (30 Days)
52.7K
257.0K
Earning Date
04-27-2026
03-09-2026
Dividend Yield
7.49%
N/A
EPS Growth
N/A
N/A
EPS
1.27
N/A
Revenue
$99,190,000.00
N/A
Revenue This Year
$2.12
N/A
Revenue Next Year
$2.94
N/A
P/E Ratio
$31.34
N/A
Revenue Growth
0.18
N/A
52 Week Low
$35.26
$2.62
52 Week High
$44.70
$11.23

Technical Indicators

Market Signals
Indicator
UHT
DSGN
Relative Strength Index (RSI) 32.08 53.32
Support Level $38.72 $9.64
Resistance Level $41.64 $11.18
Average True Range (ATR) 1.08 0.59
MACD -0.42 0.02
Stochastic Oscillator 11.22 55.19

Price Performance

Historical Comparison
UHT
DSGN

About UHT Universal Health Realty Income Trust

Universal Health Realty Income Trust is a healthcare REIT. The company is engaged in the business of investing in and leasing healthcare and human service facilities through direct ownership or through joint ventures, which aggregate into a single reportable segment. The company actively manages a portfolio of healthcare and human service facilities. The revenue and net income are generated from the operation of the investment portfolio, located throughout the United States.

About DSGN Design Therapeutics Inc.

Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.

Share on Social Networks: